Curium in advanced talks to acquire Lantheus for $7 billion

Curium is in advanced talks to buy Lantheus for $7 billion, potentially combining two major players in diagnostic radiopharmaceuticals such as the PET tracer Pylarify. No final decision has been reached.

• The proposed deal values Lantheus at $7 billion ($102 per share upfront plus $12.50 in contingent value rights).
• Lantheus produces Pylarify, a targeted PET imaging agent for prostate cancer, and has a neuroendocrine tumor PET product under FDA review.
• Separately, Curium announced the reintroduction of its cardiac SPECT tracer thallium-201 to the U.S. market after production ceased in 2022.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.